Tuesday, August 16, 2022


Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test

Latest Posts

Lytix Biopharma Announced Data from its ATLAS-IT-04 Trial

The ATLAS-IT-04 trial was an open-label, exploratory, Phase II trial assessing the effect of LTX-315 when used in combination with ACT in patients with metastatic STS. ACT with tumor infiltrating lymphocytes (TILs) is a potent treatment that can induce complete and durable tumor regression as documented in patients with melanoma. The use of ACT with TILs for patients with advanced STS has not previously been reported.

Telehealth Post Pandemic Concerns By Mark Kestner Chief Innovation Officer for MediGuru

The expression “desperate times call for desperate measures” aptly explains developments in the field of telehealth during the COVID-19 pandemic. In order to serve those forced to stay in place by the pandemic, healthcare regulators made a number of concessions that loosened controls related to patient privacy and data security in an effort to boost accessibility. In essence, telehealth practices that were a concern prior to Covid were, for the sake of serving patients, deemed acceptable.

Alleviating Transportation Woes: Technology is likely a Silver Bullet, for the Transportation Industry and Beyond By: PJ Piper, Founder & CEO, Far UV Technologies

March of 2020 was a tipping point: The sudden and surreal realization of just how perilous the human journey can be, hanging by the thinnest of threads. While the world tried to understand what the Covid-19 pandemic meant for the future, billions of people immediately learned how easily dangerous invisible pathogens could upend life, literally on a dime.

Kymanox Announces First Kymanox Executive Advisor: Fran DeGrazio

Fran DeGrazio has over 35 years of experience in technical product development, quality, regulatory, marketing, and business strategy, serving most recently as the Chief Scientific Officer at West Pharmaceutical Services.

Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced that in an independent validation study, PrismRA accurately predicted which patients with rheumatoid arthritis would not achieve EULAR good response criteria at six months of treatment using either adalimumab or etanercept.

A validation study with 68 RA patients who started either adalimumab or etanercept as their first biologic was recently presented at EULAR on June 2, 2021, along with the Sint Maartenskliniek in the Netherlands.  The study compared baseline PrismRA results with actual outcomes at six months using EULAR good response as the clinical outcome measure.

The study found a EULAR-based inadequate response in 37 out of the 68 patients, or 54.4%. The study demonstrated that patients with a molecular signature of non-response were four times more likely to achieve a EULAR inadequate response at six months than those lacking the molecular signature. Identifying those patients who will not respond to TNFi therapy in advance, before treatment begins, has the potential to reduce time spent on trial-and-error approaches and could result in improved outcomes and decreased patient burden.

“The successful validation of the novel test for EULAR inadequate response in this treat-to-target setting is promising,” said Johanna Withers, Ph.D., study co-author, and Principal Scientist at Scipher Medicine. “This could optimize care, reducing wasted time on ineffective therapies and potentially halting disease progression. Demonstrating PrismRA’s ability to accurately predict non-response in an independent cohort outside of the United States further demonstrates the tests generalizability across diverse patient populations.”

In addition to this collaboration with the Sint Maartenskliniek, Scipher Medicine also published new data on the ability of PrismRA to predict inadequate response to TNF inhibitor therapies in seronegative RA patients as well as on efforts to define high-confidence treatment response outcomes using a Monte Carlo simulation approach to evaluate the true impact of therapeutic efficacy and response.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine